Stockscreener 앱 받기
0.15%
시간 외 거래:
Pfizer Inc 주식(PFE)의 최신 뉴스
Pfizer Oncology Outlook Shifts As PADCEV Keytruda Win Nears FDA Decision - simplywall.st
Pfizer’s PADCEV Keytruda Priority Review Tests Bladder Cancer And Valuation Story - Yahoo Finance
Pfizer's Andrew Baum to Transition Role Amid Strategic Simplification - GuruFocus
CICC Initiates Coverage of Pfizer Inc. (PFE) With an Outperform Rating - Yahoo Finance
Pfizer's Strategy and Innovation Officer Andrew Baum to leave drugmaker, analyst note says - Reuters
Pfizer Inc. stock (US7170811035): Why does its post-COVID pivot matter more now for investors? - AD HOC NEWS
Mizuho reiterates BridgeBio stock rating ahead of Pfizer trial By Investing.com - Investing.com Canada
FDA Grants Priority Review for Pfizer and Astellas' Padcev with Keytruda for Bladder Cancer - Intellectia AI
Pfizer, Astellas win FDA priority review for Padcev (PFE:NYSE) - Seeking Alpha
Pfizer (PFE) and Amgen (AMGN) Expand Presence in Hong Kong - GuruFocus
Pfizer, Amgen among 22 firms to expand in Hong Kong: SCMP (PFE:NYSE) - Seeking Alpha
Seagen Inc (Acquired) stock (US8166361055): Why does its oncology pipeline still matter post-acquisi - AD HOC NEWS
Pfizer Impfstoff (Comirnaty): Post-Pandemic Revenue Drop Sparks Strategy Shift - AD HOC NEWS
Pfizer Impfstoff (Comirnaty): Post-Pandemic Pivot Challenges Traditional Vaccine Revenue - AD HOC NEWS
Where will Pfizer stock be in 3 years? - MSN
This Drug Stock Has Crushed the S&P 500 Over the Last Decade - The Motley Fool
Pfizer Inc. stock (US7170811035): Is its post-COVID pivot strong enough to unlock new upside? - AD HOC NEWS
Lobbying Update: $4,420,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Where Will Pfizer Stock Be in 3 Years? - Yahoo Finance
Pfizer’s COVID Reset Shifts Focus To Obesity Pipeline And Valuation Risks - simplywall.st
Pfizer (PFE) Valuation Check As COVID Decline And Obesity Pipeline Shift Reshape Its Outlook - Yahoo Finance
Mirae Asset Global Investments Co. Ltd. Acquires 177,689 Shares of Pfizer Inc. $PFE - MarketBeat
PFE Stock Quote Price and Forecast - CNN
Pfizer (NYSE:PFE) Trading Up 1.3%What's Next? - MarketBeat
Wilson’s Disease Market to Reach New Heights by 2034 with Advancing Gene Therapies and Strong Pipeline from Vivet Therapeutics, Pfizer, and Ultragenyx Pharmaceutical | DelveInsight - Barchart.com
Pfizer Inc. stock outperforms competitors on strong trading day - MarketWatch
Pfizer Patent Suits Seek to Block Competitors’ Dermatitis Drugs - Bloomberg Law News
Pfizer Impfstoff (Comirnaty): Post-Pandemic revenue drop raises big questions for Pfizer's future - AD HOC NEWS
Records Show Pfizer Used Sick Monkeys in Drug Testing, PETA Urges Review - PETA
Rebalancing Agents Hympavzi (Pfizer), Qfitlia (Sanofi), Alhemo (Novo Nordisk) Gain Ground in Hemophilia as Physicians Navigate Access Barriers and Expanding Treatment Complexity - Yahoo Finance
Pfizer (NYSE: PFE) CEO receives phantom stock unit award under deferred plan - Stock Titan
AbbVie vs. Pfizer: One Pharma Dividend Has a Moat — The Other Is Praying for a Pipeline Hit - Yahoo Finance
Pfizer Stock: Painful Recovery Underway (NYSE:PFE) - Seeking Alpha
Wright Investors Service Inc. Purchases 56,743 Shares of Pfizer Inc. $PFE - MarketBeat
Meropenem Market Is Booming So Rapidly | Merck & Co. • Pfizer Inc. • AstraZeneca - openPR.com
Argo Wealth Advisory LLC Takes Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. $PFE Shares Acquired by AE Wealth Management LLC - MarketBeat
Pfizer (PFE) CEO Albert Bourla receives 911 phantom stock units as deferred pay - Stock Titan
Pfizer Inc (PFE) Stock Price, Trades & News - GuruFocus
Pfizer-Backed EV-209 Trial Targets Bladder Preservation in High-Need Cancer Segment - TipRanks
Pfizer stock price forecast: sideways trading expected as PFE consolidates above key supports - Traders Union
Here Are Thursday’s Top Wall Street Analyst Research Calls: Autoliv, CoreWeave, Corning, Dicks Sporting Goods, Federated Hermes, Gitlab, PayPal, Pfizer, Okta, and More - 24/7 Wall St.
Lbp Am Sa Has $25.32 Million Stake in Pfizer Inc. $PFE - MarketBeat
KBC Group NV Purchases 706,426 Shares of Pfizer Inc. $PFE - MarketBeat
CICC Initiates Pfizer at Outperform With $33 Price Target - marketscreener.com
Assessing Pfizer (PFE) Valuation As Investor Interest Returns And Turnaround Expectations Build - simplywall.st
DND Pharmatech Wins KRW1.83 Billion Anti-Obesity Drug Formulation Contract from Pfizer; Shares Rise 3% - marketscreener.com
New weight loss drug by Pfizer shows promising results in trial - AOL.com
Pfizer's Non-Oncology Portfolio in Focus Ahead of Q1 Earnings - Yahoo Finance
How Biomarker Testing Helped a Lung Cancer Patient Get the Treatment She Needed - Pfizer
Pfizer Inc. $PFE Shares Sold by Freestone Capital Holdings LLC - MarketBeat
Pfizer Inc. stock (US7170811035): Is its wide moat strong enough to unlock new upside? - AD HOC NEWS
Assetmark Inc. Has $62.58 Million Position in Pfizer Inc. $PFE - MarketBeat
UBS Adjusts Pharma Outlook, Increases Pfizer (PFE) Price Target - Insider Monkey
Pfizer is Latest Target of FDA's Crackdown on Direct-to-Consumer, Social Media Ads - Law.com
BRAF Mutated Non-small Cell Lung Cancer Market: Rapid Increment Driven by Innovation by 2036 – DelveInsight | AbbVie, Xcovery, Sanofi, NeoImmune Tech, Merck KGaA and Pfizer, Mirati Therapeutics - Barchart
Pfizer Exec on Building Data, Process Foundation for AI - WSJ
Former Pfizer exec estimates 20,000 to 60,000 deaths from COVID shot in Germany - Todayville
How Pfizer's Oncology Portfolio Is Shaping Up Before Q1 Results - qz.com
Earnings Preview: What to Expect From Pfizer’s Report - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: InflaRx (IFRX), Pfizer (PFE) - The Globe and Mail
Wells Fargo Releases a Hold Rating on Pfizer (PFE) - The Globe and Mail
Pfizer, DoHDA talks stall as PBS listing times blow out to almost two years - Health Services Daily
Pfizer (PFE) Outperforms Broader Market: What You Need to Know - Yahoo Finance
Pfizer (NYSE:PFE) Trading Up 1.5% on Analyst Upgrade - MarketBeat
Pfizer Options Spot-On: On April 13th, 179.18K Contracts Were Traded, With 2.52 Million Open Interest - Moomoo
UBS Raises Price Target on Pfizer to $27 From $25, Maintains Neutral Rating - marketscreener.com
FDA flags Facebook ads for Pfizer’s cancer drug as misleading - Medical Marketing and Media
UBS Initiates Pfizer(PFE.US) With Hold Rating, Announces Target Price $27 - Moomoo
Guggenheim reiterates Buy on Pfizer stock ahead of earnings - Investing.com
1.29%
자본화:
|
볼륨(24시간):